GeneFerm Biotechnology Correlations
| 1796 Stock | TWD 49.95 0.65 1.32% |
The current 90-days correlation between GeneFerm Biotechnology and Alar Pharmaceuticals is 0.17 (i.e., Average diversification). The correlation of GeneFerm Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
GeneFerm Biotechnology Correlation With Market
Significant diversification
The correlation between GeneFerm Biotechnology Co and DJI is 0.07 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding GeneFerm Biotechnology Co and DJI in the same portfolio, assuming nothing else is changed.
GeneFerm |
The ability to find closely correlated positions to GeneFerm Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace GeneFerm Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back GeneFerm Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling GeneFerm Biotechnology Co to buy it.
Moving together with GeneFerm Stock
| 0.71 | 2882B | Cathay Financial Holding | PairCorr |
| 0.77 | 2882A | Cathay Financial Holding | PairCorr |
| 0.63 | 2891B | CTBC Financial Holding | PairCorr |
| 0.64 | 2330 | Taiwan Semiconductor | PairCorr |
| 0.63 | 0053 | YuantaP shares Taiwan | PairCorr |
| 0.67 | 0050 | YuantaP shares Taiwan | PairCorr |
| 0.66 | 0057 | Fubon MSCI Taiwan | PairCorr |
Moving against GeneFerm Stock
| 0.54 | 6620 | Handa Pharmaceuticals | PairCorr |
| 0.53 | 2888 | Shin Kong Financial | PairCorr |
| 0.45 | 4114 | Synmosa Biopharma | PairCorr |
| 0.37 | 6785 | Alar Pharmaceuticals | PairCorr |
| 0.33 | 2891C | CTBC Financial Holding | PairCorr |
Related Correlations Analysis
Please specify at least 3 valid symbols having historical data to build a meaningful correlation cloud. You can use symbol search above to locate your securities.
Be your own money manager
Our tools can tell you how much better you can do entering a position in GeneFerm Biotechnology without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Center Now
Portfolio CenterAll portfolio management and optimization tools to improve performance of your portfolios |
| All Next | Launch Module |
GeneFerm Biotechnology Corporate Management
Elected by the shareholders, the GeneFerm Biotechnology's board of directors comprises two types of representatives: GeneFerm Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GeneFerm. The board's role is to monitor GeneFerm Biotechnology's management team and ensure that shareholders' interests are well served. GeneFerm Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GeneFerm Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frank Hsiao | Deputy General Manager-Sales & Marketing Division | Profile | |
| Qimian Su | Head of Finance & Accounting | Profile | |
| Zongmin Chen | Independent Director | Profile | |
| Grance Chang | Chairman of the Board | Profile | |
| Benlin Chen | Director | Profile | |
| Yiren Ji | Director | Profile | |
| Jiajun Hong | Director | Profile |